AEye Reports Fourth Quarter and Full Year 2022 Results
“In 2022, we made great strides in strengthening our platform and product portfolio to drive long-term growth,” said
Q4 2022 Financials
-
Revenue of
$1.1 million in the fourth quarter of 2022. -
GAAP net loss was
$(23.7) million in the fourth quarter of 2022, or$(0.15) per share based on 161.2 million weighted average common shares outstanding. -
Non-GAAP net loss was
$(17.5) million in the fourth quarter of 2022, or$(0.11) per share based on 161.2 million weighted average common shares outstanding. -
Cash, cash equivalents, and marketable securities were
$94.2 million as ofDecember 31, 2022 .
Full Year 2022 Financials
-
Revenue of
$3.6 million in the year endedDecember 31, 2022 . -
GAAP net loss was
$(98.7) million in the year endedDecember 31, 2022 , or$(0.63) per share based on 157.4 million weighted average common shares outstanding. -
Non-GAAP net loss was
$(73.8) million in the year endedDecember 31, 2022 , or$(0.47) per share based on 157.4 million weighted average common shares outstanding.
Chief Financial Officer Transition
The company also announced today that
Conference Call and Webcast Details
The webcast and accompanying slides will be accessible via the company’s website at https://investors.aeye.ai/.
The information will be available via:
- Conference call: https://aeye.pub/41XWp9L
- Webcast: https://aeye.pub/3JpZzfm
About
AEye’s unique software-defined lidar solution enables advanced driver-assistance, vehicle autonomy, smart infrastructure, logistics and off-highway applications that save lives and propel the future of transportation and mobility. AEye’s 4Sight™ Intelligent Sensing Platform, with its adaptive sensor-based operating system, focuses on what matters most; delivering faster, more accurate, and reliable information. AEye’s 4Sight™ products, built on this platform, are ideal for dynamic applications which require precise measurement imaging to ensure safety and performance.
Non-GAAP Financial Measures
The non-GAAP measures provided in this press release should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with generally accepted accounting principles (GAAP) in
This presentation includes non-GAAP financial measures, including:
- Non-GAAP net loss which is defined as GAAP net loss plus stock-based compensation, plus expenses related to registrations on Form S-1/S-3, plus common stock purchase agreement costs, plus change in fair value of convertible note, embedded derivative and warrant liabilities, plus convertible note issuance costs, less the gain on PPP loan forgiveness; and
- Adjusted EBITDA which is defined as non-GAAP net loss plus amortization and depreciation expense, plus interest expense and other, less interest income and other, plus provision for income tax expense.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements within the meaning of the federal securities laws, including the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “continue,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “predict,” “plan,” “may,” “should,” “will,” “would,” “potential,” “seem,” “seek,” “outlook,” and similar expressions that predict or indicate future events or trends, or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward looking statements included in this press release include statements about AEye’s platform and product portfolio, the Company’s strategic plan, and the Company’s expected future growth, among others. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are very difficult or impossible to predict and will differ from the assumptions. Many actual events and circumstances are beyond the control of
Readers are cautioned not to put undue reliance on forward-looking statements;
Consolidated Balance Sheets (In thousands) (Unaudited) |
|||||||
As of |
|||||||
2022 |
2021 |
||||||
ASSETS | |||||||
Current Assets: | |||||||
Cash and cash equivalents | $ |
19,064 |
|
$ |
14,183 |
|
|
Marketable securities |
75,135 |
|
149,824 |
|
|||
Accounts receivable, net |
617 |
|
4,222 |
|
|||
Inventories, net |
4,553 |
|
4,085 |
|
|||
Prepaid and other current assets |
6,181 |
|
5,051 |
|
|||
Total current assets |
105,550 |
|
177,365 |
|
|||
Right-of-use assets |
15,502 |
|
— |
|
|||
Property and equipment, net |
7,665 |
|
5,129 |
|
|||
Restricted cash |
2,150 |
|
2,150 |
|
|||
Other noncurrent assets |
2,473 |
|
1,509 |
|
|||
Total assets | $ |
133,340 |
|
$ |
186,153 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current Liabilities: | |||||||
Accounts payable | $ |
3,218 |
|
$ |
2,542 |
|
|
Accrued expenses and other current liabilities |
9,764 |
|
8,739 |
|
|||
Contract liabilities |
987 |
|
2,287 |
|
|||
Convertible notes |
8,594 |
|
— |
|
|||
Total current liabilities |
22,563 |
|
13,568 |
|
|||
Operating lease liabilities, noncurrent |
16,681 |
|
— |
|
|||
Deferred rent, noncurrent |
— |
|
3,032 |
|
|||
Other noncurrent liabilities |
126 |
|
786 |
|
|||
Total liabilities |
39,370 |
|
17,386 |
|
|||
Stockholders' Equity: | |||||||
Preferred stock |
— |
|
— |
|
|||
Common stock |
16 |
|
16 |
|
|||
Additional paid-in capital |
345,742 |
|
320,937 |
|
|||
Accumulated other comprehensive loss |
(1,279 |
) |
(391 |
) |
|||
Accumulated deficit |
(250,509 |
) |
(151,795 |
) |
|||
Total stockholders’ equity |
93,970 |
|
168,767 |
|
|||
Total liabilities and stockholders’ equity | $ |
133,340 |
|
$ |
186,153 |
|
|
Consolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) |
|||||||||||||||
Three months ended |
Year ended |
||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
||||
Revenue: | |||||||||||||||
Prototype sales | $ |
561 |
|
$ |
416 |
|
$ |
1,743 |
|
$ |
1,004 |
|
|||
Development contracts |
531 |
|
1,388 |
|
1,904 |
|
2,003 |
|
|||||||
Total revenue |
1,092 |
|
1,804 |
|
3,647 |
|
3,007 |
|
|||||||
Cost of revenue |
3,115 |
|
2,100 |
|
8,732 |
|
3,637 |
|
|||||||
Gross loss |
(2,023 |
) |
(296 |
) |
(5,085 |
) |
(630 |
) |
|||||||
Operating Expenses: | |||||||||||||||
Research and development |
9,335 |
|
7,513 |
|
37,644 |
|
26,543 |
|
|||||||
Sales and marketing |
4,912 |
|
4,059 |
|
19,317 |
|
10,548 |
|
|||||||
General and administrative |
7,709 |
|
11,668 |
|
36,762 |
|
25,514 |
|
|||||||
Total operating expenses |
21,956 |
|
23,240 |
|
93,723 |
|
62,605 |
|
|||||||
Loss from operations |
(23,979 |
) |
(23,536 |
) |
(98,808 |
) |
(63,235 |
) |
|||||||
Other income (expense): | |||||||||||||||
Change in fair value of convertible note, embedded derivative liability, and warrant liabilities |
(139 |
) |
1 |
|
(14 |
) |
223 |
|
|||||||
Gain on PPP loan forgiveness |
— |
|
— |
|
— |
|
2,297 |
|
|||||||
Interest income and other |
436 |
|
487 |
|
1,545 |
|
561 |
|
|||||||
Interest expense and other |
(41 |
) |
(1,986 |
) |
(1,379 |
) |
(4,857 |
) |
|||||||
Total other income (expense), net |
256 |
|
(1,498 |
) |
152 |
|
(1,776 |
) |
|||||||
Provision for income tax expense |
19 |
|
— |
|
58 |
|
— |
|
|||||||
Net loss | $ |
(23,742 |
) |
$ |
(25,034 |
) |
$ |
(98,714 |
) |
$ |
(65,011 |
) |
|||
Per Share Data | |||||||||||||||
Net loss per common share (basic and diluted) | $ |
(0.15 |
) |
$ |
(0.16 |
) |
$ |
(0.63 |
) |
$ |
(0.60 |
) |
|||
Weighted average common shares outstanding (basic and diluted) |
161,205,764 |
|
154,616,998 |
|
157,368,707 |
|
109,055,894 |
|
|||||||
Consolidated Statements of Cash Flows (In thousands) (Unaudited) |
|||||||
Year ended |
|||||||
|
|
2022 |
|
|
2021 |
||
Cash flows from operating activities: | |||||||
Net loss | $ |
(98,714 |
) |
$ |
(65,011 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Depreciation and amortization |
1,422 |
|
1,014 |
|
|||
Noncash lease expense relating to operating lease right-of-use assets |
1,338 |
|
— |
|
|||
Noncash common stock purchase agreement costs |
— |
|
1,583 |
|
|||
Inventory write-downs, net of scrapped inventory |
675 |
|
1,203 |
|
|||
Change in fair value of convertible note, embedded derivative liability, and warrant liabilities |
14 |
|
(223 |
) |
|||
Noncash gain on PPP loan forgiveness |
— |
|
(2,297 |
) |
|||
Stock-based compensation |
23,959 |
|
10,018 |
|
|||
Convertible note issuance costs |
474 |
|
— |
|
|||
Amortization of debt issuance costs |
— |
|
725 |
|
|||
Amortization of debt discount |
— |
|
752 |
|
|||
Realized loss on redemption of marketable securities |
77 |
|
— |
|
|||
Amortization of premiums on marketable securities, net of change in accrued interest |
1,086 |
|
310 |
|
|||
Other |
— |
|
287 |
|
|||
Changes in operating assets and liabilities: | |||||||
Accounts receivable, net |
3,605 |
|
(4,066 |
) |
|||
Inventories, current and noncurrent, net |
(2,634 |
) |
(2,633 |
) |
|||
Prepaid and other current assets |
(1,130 |
) |
(3,655 |
) |
|||
Other noncurrent assets |
527 |
|
(1,483 |
) |
|||
Accounts payable |
839 |
|
557 |
|
|||
Accrued expenses and other current liabilities |
85 |
|
5,496 |
|
|||
Operating lease liabilities |
(1,341 |
) |
— |
|
|||
Deferred rent |
— |
|
(538 |
) |
|||
Contract liabilities |
(1,931 |
) |
2,258 |
|
|||
Net cash used in operating activities |
(71,649 |
) |
(55,703 |
) |
|||
Cash flows from investing activities: | |||||||
Purchase of property and equipment |
(4,200 |
) |
(1,021 |
) |
|||
Proceeds from redemptions and maturities of marketable securities |
96,592 |
|
— |
|
|||
Purchase of available-for-sale securities |
(23,929 |
) |
(150,525 |
) |
|||
Net cash provided by (used in) investing activities |
68,463 |
|
(151,546 |
) |
|||
Cash flows from financing activities: | |||||||
Proceeds from exercise of stock options |
1,174 |
|
150 |
|
|||
Proceeds from Business Combination and PIPE financing |
— |
|
256,811 |
|
|||
Transaction costs related to Business Combination and PIPE financing |
— |
|
(52,372 |
) |
|||
Proceeds from the issuance of convertible notes |
9,850 |
|
8,045 |
|
|||
Payments for convertible note redemptions |
(874 |
) |
— |
|
|||
Proceeds from bank loan |
— |
|
10,000 |
|
|||
Principal payments on bank loans |
— |
|
(13,333 |
) |
|||
Payment of 2022 convertible note issuance costs |
(324 |
) |
— |
|
|||
Payment of debt issuance costs |
— |
|
(717 |
) |
|||
Taxes paid related to the net share settlement of equity awards |
(4,621 |
) |
— |
|
|||
Repurchase of stock options |
— |
|
(1,500 |
) |
|||
Proceeds from issuance of common stock under the Common Stock Purchase Agreement |
2,891 |
|
— |
|
|||
Payment of transaction costs related to the Common Stock Purchase Agreement |
(29 |
) |
— |
|
|||
Net cash provided by financing activities |
8,067 |
|
207,084 |
|
|||
Net increase in cash, cash equivalents and restricted cash |
4,881 |
|
(165 |
) |
|||
Cash, cash equivalents and restricted cash at beginning of period |
16,333 |
|
16,498 |
|
|||
Cash, cash equivalents and restricted cash at end of period | $ |
21,214 |
|
$ |
16,333 |
|
|
Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except share and per share data) (Unaudited) |
|||||||||||||||
Three months ended |
Year ended |
||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
||||
GAAP net loss | $ |
(23,742 |
) |
$ |
(25,034 |
) |
$ |
(98,714 |
) |
$ |
(65,011 |
) |
|||
Non-GAAP adjustments: | |||||||||||||||
Stock-based compensation |
5,956 |
|
3,496 |
|
23,959 |
|
10,018 |
|
|||||||
Expenses related to registration statement on Form S-1s/S-3s |
68 |
|
— |
|
372 |
|
2,198 |
|
|||||||
Common stock purchase agreement transaction costs |
— |
|
1,583 |
|
29 |
|
1,583 |
|
|||||||
Change in fair value of convertible note, embedded derivative liability, and warrant liabilities |
139 |
|
(1 |
) |
14 |
|
(223 |
) |
|||||||
2022 convertible note issuance costs |
93 |
|
— |
|
530 |
|
— |
|
|||||||
Gain on PPP loan forgiveness |
— |
|
— |
|
— |
|
(2,297 |
) |
|||||||
Non-GAAP net loss | $ |
(17,486 |
) |
$ |
(19,956 |
) |
$ |
(73,810 |
) |
$ |
(53,732 |
) |
|||
Depreciation and amortization expense |
628 |
|
245 |
|
1,422 |
|
1,014 |
|
|||||||
Interest income and other |
(436 |
) |
(487 |
) |
(1,545 |
) |
(561 |
) |
|||||||
Interest expense and other |
(52 |
) |
403 |
|
876 |
|
3,274 |
|
|||||||
Provision for income tax expense |
19 |
|
— |
|
58 |
|
— |
|
|||||||
Adjusted EBITDA | $ |
(17,327 |
) |
$ |
(19,795 |
) |
$ |
(72,999 |
) |
$ |
(50,005 |
) |
|||
GAAP net loss per share attributable to common stockholders: | |||||||||||||||
Basic and diluted | $ |
(0.15 |
) |
$ |
(0.16 |
) |
$ |
(0.63 |
) |
$ |
(0.60 |
) |
|||
Non-GAAP net loss per share attributable to common stockholders: | |||||||||||||||
Basic and diluted | $ |
(0.11 |
) |
$ |
(0.13 |
) |
$ |
(0.47 |
) |
$ |
(0.49 |
) |
|||
Shares used in computing GAAP net loss per share attributable to common stockholders: | |||||||||||||||
Basic and diluted |
161,205,764 |
|
154,616,998 |
|
157,368,707 |
|
109,055,894 |
|
|||||||
Shares used in computing Non-GAAP net loss per share attributable to common stockholders: | |||||||||||||||
Basic and diluted |
161,205,764 |
|
154,616,998 |
|
157,368,707 |
|
109,055,894 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005330/en/
Media:
jennifer@aeye.ai
925-400-4366
AEye@landispr.com
415-717-9133
Investors:
310-622-8249
Aeye@finprofiles.com
Source: